Showing results (161-170 of 196) with videos related to

Sort By:
Pageof 20
The Lancet. Oncology|September 18, 2016
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre studySusan O'Brien, Jeffrey A Jones, Steven E Coutre, et al.
American Journal of Hematology|September 24, 2017
Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findingsPaul J Hampel, Kari G Chaffee, Rebecca L King, et al.
Blood Cancer Journal|January 29, 2022
Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?Rebecca L King, Alia Gupta, Paul J Kurtin, et al.
JACC. Cardiooncology|May 22, 2024
Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation in Patients With Chronic Lymphocytic LeukemiaGeorgios Christopoulos, Zachi I Attia, Sara J Achenbach, et al.
ESMO Open|September 3, 2021
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancersE E Dumbrava, S G Call, H J Huang, et al.
Blood Cancer Journal|September 1, 2022
Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinibPaul J Hampel, Kari G Rabe, Timothy G Call, et al.
American Journal of Hematology|April 13, 2020
Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic indexGeffen Kleinstern, Daniel R O'Brien, Xing Li, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 25, 2010
Genetic susceptibility variants for chronic lymphocytic leukemiaSusan L Slager, Lynn R Goldin, Sara S Strom, et al.
Blood Advances|March 6, 2023
Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLLRosalie Griffin, Julia E Wiedmeier-Nutor, Sameer A Parikh, et al.
Cancer Medicine|March 19, 2020
The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practiceSameer A Parikh, Sara J Achenbach, Timothy G Call, et al.
Pageof 20